Sunovion announced the availability of Utibron Neohaler (indacaterol/glycopyrrolate) inhalation powder for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
Sunovion has taken over US commercialization rights from Novartis for Utibron Neohaler, Seebri Neohaler, and Arcapta Neohaler. Utibron Neohaler combines indacaterol, a long-acting beta agonist (LABA), and glycopyrrolate, a long-acting muscarinic antagonist (LAMA). It was initially approved by the FDA in October 2015.
Utibron Neohaler is available as 27.5mcg/15.6mcg strength capsules containing dry powder for oral inhalation with the Neohaler device. Seebri Neohaler and Arcapta Neohaler will be launched under Sunovion between April 2017 and March 2018.
Reference
- Important safety information and indication for Utibron Neohaler. Utibron Neohaler. Accessed April 13, 2017.
This article originally appeared on Clinical Advisor
